Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Verici DxLSE:VRCI Gross Margin % is 72.94% as of Dec. 2025, which is 6% below its 10-year median of 77.46. The stock has 3 warning signs investors should review. Among 194 Medical Diagnostics & Research companies, Verici Dx ranks better than 82.99% on this metric.
Gross Margin % is calculated as gross profit divided by its revenue. Verici Dx's Gross Profit for the
six
months ended in Dec. 2025 was £0.95 Mil. Verici Dx's Revenue for the
six
months ended in Dec. 2025 was £1.31 Mil. Therefore, Verici Dx's Gross Margin % for the quarter that ended in Dec. 2025 was 72.94%.
The historical rank and industry rank for Verici Dx's Gross Margin % or its related term are showing as below:
LSE:VRCI'
s Gross Margin % Range Over the Past 10 Years
Min: 77.41 Med: 77.46 Max: 77.46
Current: 77.41
During the past 6 years, the highestGross Margin % of Verici Dx was 77.46%. The lowest was 77.41%. And the median was 77.46%.
LSE:VRCI's Gross Margin % is ranked better than 82.99% of 194
companies
in the Medical Diagnostics & Research industry
Industry Median: 51.14
vs LSE:VRCI: 77.41
Verici Dx had a gross margin of 72.94% for the quarter that ended in Dec. 2025 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Verici Dx was 0.00% per year.
Verici Dx (LSE:VRCI) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Verici Dx had a gross margin of 72.94% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Verici Dx Gross Margin % Related Terms
Verici Dx Gross Margin % Historical Data
* Premium members only.
The historical data trend for Verici Dx's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:VRCI vs TMO, DHR, IDXX: Gross Margin % Comparison
For the Diagnostics & Research subindustry, Verici Dx's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Verici Dx Gross Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Verici Dx's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Verici Dx's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Verici Dx (LSE:VRCI) has a Gross Margin % of 72.94% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Verici Dx and its competitors. This is near median its historical median of 77.46. Over the past decade, Verici Dx's Gross Margin % has ranged from 77.41 to 77.46. According to the industry distribution chart, Verici Dx ranks #33 out of 194 companies in the Medical Diagnostics & Research industry, placing it in the top 17%.
Is Verici Dx's Gross Margin % too high?
Verici Dx's current Gross Margin % of 72.94% is near median its 10-year median of 77.46. Over the past 10 years, this metric has ranged from a low of 77.41 to a high of 77.46. The Medical Diagnostics & Research industry median Gross Margin % is 51.14. Verici Dx's value of 72.94% is 42.6% above this industry median. Based on the distribution chart, Verici Dx ranks #33 out of 194 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers.
How does Verici Dx's Gross Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Verici Dx ranks #33 out of 194 companies for Gross Margin %. This places Verici Dx in the top 17% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 51.14. Verici Dx's value of 72.94% is 42.6% above this benchmark. Historically, Verici Dx's own Gross Margin % has ranged from 77.41 to 77.46 over the past decade. While the company's 10-year median is 77.46 vs. the industry median of 51.14, Verici Dx has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Medical Diagnostics & Research company?
The median Gross Margin % among Medical Diagnostics & Research companies is 51.14, based on 194 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Verici Dx's current Gross Margin % of 72.94% is 42.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Verici Dx and its competitors. For the Medical Diagnostics & Research industry, the median Gross Margin % is 51.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Verici Dx's current Gross Margin % is 72.94%, which is near median its own 10-year median of 77.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Verici Dx stock overvalued right now?
Verici Dx (LSE:VRCI) has a current Gross Margin % of 72.94%. The current Gross Margin % is 72.94%, which is near median its 10-year median of 77.46 and 42.6% above the Medical Diagnostics & Research industry median of 51.14. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Verici Dx (LSE:VRCI), the current Gross Margin % is 72.94% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Verici Dx PLC is an immuno-diagnostics development company. The company is focused on the development of prognostic and diagnostic tests for kidney transplant patients. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; Tuteva, a post-transplant diagnostic focused upon acute cellular rejection, including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels; and Protega will utilize RNA gene signatures to more accurately risk stratify outcome from fibrosis in a transplant patient. The business of the Group comprises a single activity, which of the development of prognostic and diagnostic tests for kidney transplant patients.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:VRCI has been successfully added to your 
